ResearchMoz.us include new market research report "China Heparin Industry Report, 2012-2014" to its huge collection of research reports.
China, abundant in heparin raw materials, has become one of the worlds largest heparin API producers and exporters, owning to the quality of heparin API having won international recognition gradually. Due to the euro debt crisis, the global market suffered a deep recession. Coupled that the heparin export standard has lifted, Chinas export volume of heparin API was no more than 105.2 tons in 2011, approximating 14.6 trillion units (measured by 140IU/mg), with the proportion of around 45.9% in the global demand during the same period.
Leading heparin API suppliers worldwide include Shenzhen Hepalink Pharmaceutical, Changzhou Qianhong Bio-Pharma, Yantai Dongcheng Biochemicals and Nanjing King-Friend Biochemical Pharmaceutical, which have ranked top 4 industrial players by export for several years in a row, with the combined export value making up more than 70% of Chinas total export value of heparin. There is no distinct change in terms of the export pattern. However, the export prices of Chinas top 10 heparin exporters witnessed a downward mobility in 2011-2012H1. Nevertheless, it was not the same case for Dongying Tiandong Pharmaceutical and Jiangsu Medicine Health Care Article Imp. & Exp. (Group), whose export prices increased by 3.8% and 2.1% year-on-year respectively in Jan.-May, 2012, due to the improved quality of exported products as well as the low cardinal number of exported prices in the preceding year.
To know more about this reports, please visit @ China Heparin Industry Market
Meanwhile, Chinese heparin API flagship enterprises including Shenzhen Hepalink Pharmaceutical, Changzhou Qianhong Bio-Pharma, Yantai Dongcheng Biochemicals, Hebei Changshan Biochemical Pharmaceutical and Nanjing King-Friend Biochemical Pharmaceutical are projected to expand their capacities and improve the heparin industry chains. Among these tycoons, the first four ones have made IPO, while Nanjing King-Friend Biochemical Pharmaceutical is also preparing for IPO by accepting tutoring. According to public information issued by related enterprises, the heparin API capacity of China will increase by more than 18 trillion units by 2014, with the total capacity expected to exceed 30 trillion units, making up over 70% of the global demand.
Although China is a large country with rich heparin API, the downstream production of general heparin preparation and low molecular weight heparin preparation is still at the initial stage. In the high-end low molecular weight heparin preparation market, especially, joint ventures and foreign brands including Sanofi-Aventis, Pfizer and GSK have eroded into the Chinese market. According to China Pharmaceutical Industry Association, imported low molecular weight heparin calcium accounted for more than 60% of the total procurement of such products of representative hospitals in 22 Chinese cities in 2011.
However, with the improvement of R&D and technological strength, the competitiveness of made-in-China low molecular weight heparin preparation market is increasingly enhancing. A case in point is Hebei Changshan Biochemical Pharmaceutical Co., Ltd, the capacity of low molecular weight heparin calcium injection of which soared from 4 million pcs to 10 million pcs in 2011, with the sales increased by 68.4% year-on-year to RMB86.93 million, compared to the sales of RMB117 million in 2012H1, a year-on-year rise of 237.6%.
Find newly published Market Research Reports @ http://www.researchmoz.us/report.html
Contact: email@example.com for further information.